drugset / Trial / NCT06245122
A Study of CS23546 in Subjects With Advanced Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objectives of this study are to characterize the safety and tolerability of CS23546 and to evaluate the pharmacokinetic (PK) characteristics and recommended phase 2 dose (RP2D) of CS23546 in subjects with advanced tumors.
Timeline
- Start
- 2024-03-27
- Primary completion
- 2027-02-28
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS23546 | Unknown | — | Oral |